Literature DB >> 10218762

Clinical and laboratory manifestations of anti-factor V antibodies.

T L Ortel1.   

Abstract

Factor V is a large, multi-domain glycoprotein that exhibits both procoagulant and anticoagulant activity. Anti-factor V antibodies may develop by several mechanisms and, depending on their epitope specificity, may produce hemorrhagic or thromboembolic complications. The clinical laboratory is an essential component in diagnosing these antibodies, and therapeutic management depends on the predominant clinical manifestations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10218762     DOI: 10.1016/s0022-2143(99)90062-8

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  10 in total

Review 1.  Acquired factor V inhibitors: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

2.  Exposure of mice to topical bovine thrombin induces systemic autoimmunity.

Authors:  J G Schoenecker; R K Johnson; A P Lesher; J D Day; S D Love; M R Hoffman; T L Ortel; W Parker; J H Lawson
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

3.  Acquired factor v inhibitor developing after treatment with dabigatran etexilate methanesulfonate: a case report and review of the literature.

Authors:  Yasunobu Sekiguchi; Hitomi Yoshikawa; Asami Shimada; Hidenori Imai; Mutsumi Wakabayashi; Keiji Sugimoto; Noriko Nakamura; Tomohiro Sawada; Tetsuo Ichinose; Dai Ozaki; Norio Komatsu; Masaaki Noguchi
Journal:  Indian J Hematol Blood Transfus       Date:  2014-03-06       Impact factor: 0.900

4.  A high titer of acquired factor V inhibitor in a hemodialysis patient who developed arterial thrombosis.

Authors:  Hina Ogawa; Masayoshi Souri; Kazunori Kanouchi; Tsukasa Osaki; Rie Ohkubo; Tomoko Kawanishi; Sachiko Wakai; Keita Morikane; Akitada Ichinose
Journal:  Int J Hematol       Date:  2018-11-16       Impact factor: 2.490

5.  A Possible Allergic Reaction Case to Thrombin Injected into Pseudoaneurysm After Radiofrequency Ablation.

Authors:  Lahati Ha; Sze-Wa Yiu; Fang-Fang Wang; Jiang-Li Han
Journal:  Am J Case Rep       Date:  2019-10-11

6.  A Case of Acquired Factor V Deficiency in Patient with Bleeding.

Authors:  Davide Vetri; Giovanni Lumera; Salvatore Tarascio; Salvatore Scuto; Elisa Marino; Giuliana Barcellona; Salvatore Santo Signorelli
Journal:  TH Open       Date:  2020-04-20

7.  Challenges in management of unusual acquired factor V deficiency: A case report.

Authors:  Kiyoshi Takemoto; Osamu Hamada; Koichi Kitamura; Naoki Fujiwara; Yoshitaka Miyakawa
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

8.  Acquired factor V inhibitors after allogeneic hematopoietic stem cell transplantation in a dog.

Authors:  Joseph Masciana; Nathan Peterson; John Chretin
Journal:  J Vet Intern Med       Date:  2020-07-20       Impact factor: 3.333

9.  Development of Acquired Factor V Inhibitor After Surgical Procedure Without the Use of Fibrin Tissue Adhesives: A Case Report.

Authors:  Hirohisa Hirata; Yoshihiko Sakurai; Tomohiro Takeda; Tetsuya Kasetani; Takeshi Morita
Journal:  Cureus       Date:  2021-01-14

10.  Acquired Factor V Inhibitor Complicated with Immune Thrombocytopenia.

Authors:  Fuka Mima; Ryota Minami; Mizuki Asako; Hitomi Matsunaga; Yuri Fujita; Yoshimi Takimoto; Sonoko Senda; Wataru Nakahara; Mako Ikeda; Shuji Ueda
Journal:  Intern Med       Date:  2021-06-26       Impact factor: 1.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.